GlassScriptPhysician profile
Brian M Davis
NPI 1083796890
$1,378.52
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $975 · 2020: $404.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $188.38 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $134.81 | 2019 | |
| Mallinckrodt Hospital Products INC. | $130.63 | 2020 | |
| Janssen Scientific Affairs, LLC | $124.99 | 2019 | |
| Pfizer INC. | $120.39 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $119.79 | 2019 | |
| Horizon Therapeutics Plc | $114.16 | 2019 | |
| Novartis Pharmaceuticals Corporation | $108.75 | 2019 | |
| Abbvie INC. | $100.00 | 2019 | |
| Lilly USA, LLC | $85.76 | 2019 | |
| Galderma Laboratories, L.P. | $77.33 | 2019 | |
| Vyne Pharmaceuticals INC. | $53.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $20.53 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.